

Targeted Design.



Identify the presence and **ACTIVITY** of a high-risk HPV infection.^{1,2}



Equivalent sensitivity to DNA-based tests, with superior specificity.³⁻⁵



Next generation genotyping.

Aptima® mRNA HPV testing: detects E6/E7 mRNA. The expression of E6/E7 is indicative of the HPV infections most likely to lead to disease. The Aptima® HPV assay maximizes the benefits of screening while minimizing the potential harm.^{1,2}

Studies have shown that while nearly all sexually active men and women will have HPV at some point in their lives, very few infections will progress to cancer.⁶

Benefits of Aptima mRNA

Identify the presence and ACTIVITY of a high-risk HPV infection

- ▶ The Aptima® HPV assay targets E6/E7 mRNA and identifies high-risk HPV infections that are present and active.^{1,2}
- ▶ Studies show mRNA identifies the presence and activity of a high-risk HPV infection. HPV DNA tests only identify the presence of any of the 14 high-risk types.^{1,2}
- ▶ E6/E7 mRNA expression is indicative of the HPV infections most likely to lead to disease.^{1,2}

Equivalent sensitivity to DNA-based tests with superior specificity

- ▶ Several studies show the Aptima HPV assay provides the same excellent sensitivity expected from DNA-based tests. Excellent sensitivity means minimizing false-negative results.³⁻⁵
- ▶ The Aptima HPV assay shows superior specificity versus DNA-based testing. The Clinical Evaluation of Aptima mRNA (CLEAR) clinical trial revealed that the Aptima HPV assay had 24% fewer false-positive test results than the DNA-based test.³
- ▶ Minimizing false-positive results helps the clinician target the right patients for colposcopy. This can:
 - Minimize difficult patient conversations.
 - Minimize the potential for unnecessary colposcopies and biopsies.
 - Minimize unnecessary cost to the patient.

Next generation genotyping

- ▶ The Aptima HPV Genotyping assay targets types 16 and 18/45, which are associated with up to 94% of HPV related cervical adenocarcinomas.⁷
- ▶ Type 45 is the third most common HPV type of invasive cervical cancer.^{7,8}
- ▶ The addition of type 45 identifies more women at risk for adenocarcinoma, with minimal impact to colposcopy.⁷

Years of long term safety

- ▶ The mRNA based Aptima HPV assay has up to 7 years of continuous follow up in cervical cancer screening.^{9,10}



References: 1. Tinelli A, et al. HPV viral activity by mRNA-HPV molecular analysis to screen the transforming infections in precancer cervical lesions. *Curr Pharm Biotechnol*. 2009;10(8):767-771. 2. Cuschieri K, et al. Human papillomavirus type specific DNA and RNA persistence—implications for cervical disease progression and monitoring. *J Med Virol*. 2004;73(1):65-70. doi:10.1002/jmv.20062 3. Aptima HPV assay [package insert]. AW-12820 003. San Diego, CA; Hologic, Inc., 2019. Table #13. 4. Iftner T, et al. Head-to-head comparison of the RNA-based Aptima human papillomavirus (HPV) assay and the DNA-based hybrid capture 2 HPV test in a routine screening population of women aged 30 to 60 years in Germany. *J Clin Microbiol*. 2015;53(8):2509-2516. 5. Cuzick J, et al. Comparing the performance of six human papillomavirus tests in a screening population. *Br J Cancer*. 2013;108:908-913. doi:10.1038/bjc.2013.22 6. CDC. Genital HPV Infection - CDC Fact Sheet. <https://www.cdc.gov/std/hpv/HPV-FS-July-2017.pdf>. Published July 2017. Accessed May 31, 2019. 7. de Sanjose S, et al. Human papillomavirus genotype attribution in invasive cervical cancer: a retrospective cross-sectional worldwide study. *Lancet Oncol*. 2010;11(11):1048-1056. doi:10.1016/S1473-2045(10)70230-8 8. Hopenhayn C, et al. Prevalence of human papillomavirus types in invasive cervical cancers from 7 US cancer registries before vaccine introduction. *J Low Genit Tract Dis*. 2014;18(2):182-189. doi: 10.1097/LGT.0b013e3182a577c7 9. Iftner T, et al. The longitudinal clinical performance of the RNA-based AHPV Human Papillomavirus (HPV) Assay in comparison to the DNA-based Hybrid Capture 2 HPV Test in 2 consecutive screening rounds with a 6-year interval in Germany. *J Clin Microbiol*. 2018. doi:10.1128/JCM.01177-18 (GAST) 10. Forslund O, et al. HPV-mRNA and HPV-DNA detection in samples taken up to seven years before dysplasia of cervix uteri. *Int J Cancer*. 2018; doi:10.1002/ijc.31819

SS-00764-001 Rev. 001 © 2019 Hologic, Inc. All rights reserved. Hologic, Aptima and associated logos are trademarks and/or registered trademarks of Hologic, Inc. and/or its subsidiaries in the United States and/or other countries.

Aptima® HPV Assay